Welcome to our dedicated page for Actuate Therapeutics news (Ticker: ACTU), a resource for investors and traders seeking the latest updates and insights on Actuate Therapeutics stock.
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), for high-impact, difficult-to-treat cancers. The ACTU news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how Actuate’s oncology programs evolve over time.
Recent news from Actuate emphasizes clinical data for elraglusib across multiple tumor types. The company has reported that its randomized Phase 2 Actuate-1801 Part 3B trial in first-line metastatic pancreatic ductal adenocarcinoma met its primary endpoint, with a statistically significant overall survival benefit for elraglusib plus gemcitabine/nab-paclitaxel compared with chemotherapy alone. Additional updates describe immune and genomic biomarker findings that may help explain responses and guide future studies.
News items also highlight elraglusib’s activity in other settings, including a Phase II trial in recurrent, metastatic salivary gland carcinoma and the Actuate-1902 Phase 1/2 study in refractory pediatric cancers such as Ewing sarcoma and neuroblastoma. Actuate has announced complete and partial responses, durable stable disease, and biomarker associations that support further development in these rare and challenging indications.
Beyond clinical results, ACTU news covers corporate and regulatory milestones, such as public and private financings, registration statements, and collaborations. Examples include a securities purchase agreement for common stock and warrants, an underwritten public offering of common stock, and a collaboration with Incyte Corporation and UPMC Hillman Cancer Center to evaluate elraglusib with retifanlimab and modified FOLFIRINOX in advanced pancreatic cancer.
Investors and followers of biotechnology and oncology can use the Actuate Therapeutics news page to monitor trial readouts, regulatory plans, financing transactions, and partnership updates related to the company’s GSK-3β–targeted cancer programs.
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on cancer therapies, has successfully closed a $17.25 million public offering of common stock. The offering included 2,464,286 shares at $7.00 per share, with the full exercise of the over-allotment option adding 321,428 shares.
The company plans to use the net proceeds of $15.62 million for working capital and general corporate purposes. Lucid Capital Markets served as the sole book-running manager, while Titan Partners Group acted as financial advisor for the offering.
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on cancer therapies through GSK-3β inhibition, has announced the pricing of its public offering of 2,142,858 shares at $7.00 per share.
The offering, expected to close on September 11, 2025, aims to raise $15.0 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to 321,428 additional shares. Lucid Capital Markets is serving as the sole book-running manager, with Titan Partners Group acting as financial advisor.
The proceeds will be used for working capital and general corporate purposes. The offering is being made pursuant to an effective shelf registration statement on Form S-3.
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company developing cancer therapies through GSK-3β inhibition, has announced a proposed public offering of common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of shares at the public offering price, less underwriting discounts.
The offering, managed by Lucid Capital Markets as sole book-running manager, will be conducted under an effective S-3 shelf registration. Proceeds will be used for working capital and general corporate purposes. The completion and terms of the offering are subject to market conditions.
Actuate Therapeutics (NASDAQ: ACTU) has announced the initiation of a Phase 1b trial studying the combination of its drug elraglusib with Incyte's PD-1 inhibitor retifanlimab and mFOLFIRINOX as a frontline therapy for advanced pancreatic cancer. The trial, named RiLEY (NCT06896188), will be conducted at UPMC Hillman Cancer Center.
The study will initially enroll up to 12 patients with advanced pancreatic adenocarcinoma, with potential for expansion based on interim results. In a recent Phase 2 study, elraglusib combined with gemcitabine/nab-paclitaxel showed promising results, including a 37% reduction in death risk and doubled 12-month survival rate in metastatic pancreatic cancer patients.
The collaboration between Actuate, UPMC Hillman Cancer Center, and Incyte aims to explore synergistic opportunities in treatment-naïve patients, building on elraglusib's demonstrated immune-modulating properties.
Actuate Therapeutics (NASDAQ:ACTU) has announced positive results from its Phase 1 trial evaluating elraglusib in pediatric patients with refractory malignancies. The study demonstrated remarkable outcomes in Ewing Sarcoma (EWS), with 2 out of 10 patients achieving complete responses and two additional patients showing stable disease.
The trial also reported a partial response in a patient with desmoplastic small-round-cell tumor (DSRCT). Based on these encouraging results, Actuate plans to advance to a Phase 2 trial in children, adolescents, and adults with relapsed/refractory EWS, expected to initiate in 2026, subject to funding.
Elraglusib, which targets glycogen synthase kinase-3 beta (GSK-3β), could potentially become a first-in-class therapy for EWS, where no approved targeted therapies currently exist.
Actuate Therapeutics (NASDAQ: ACTU) reported significant results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for metastatic pancreatic cancer treatment. Patients receiving at least one cycle showed improved median overall survival of 12.5 months vs 8.5 months in the control group, with a 43% reduction in death risk.
The trial demonstrated enhanced outcomes with elraglusib/GnP combination, including disease control rate of 53.4% vs 44.8% and overall response rate of 37.9% vs 29.3%. Notably, patients with liver metastases experienced a 2.5-fold increase in 1-year overall survival and 38% reduced death risk compared to control, with 13.6% survival probability at 18 months versus 0% in the control group.